Difference between revisions of "Atezolizumab (Tecentriq)"
Jump to navigation
Jump to search
m |
|||
| Line 2: | Line 2: | ||
Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.<ref>Naiyer A. Rizvi, Laura Quan Man Chow, Luc Yves Dirix, Scott N. Gettinger, Michael S. Gordon, Fairooz F. Kabbinavar, Joachim Von Pawel, Jean-Charles Soria, Colombe Chappey, Ahmad Mokatrin, Alan Sandler, Daniel Waterkamp, David R. Spigel. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting abstract TPS8123. [http://meetinglibrary.asco.org/content/128983-144 link to abstract]</ref><ref>[http://www.roche.com/media/store/releases/med-cor-2015-08-17.htm Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer] Roche.com, 8/17/2015.</ref> | Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.<ref>Naiyer A. Rizvi, Laura Quan Man Chow, Luc Yves Dirix, Scott N. Gettinger, Michael S. Gordon, Fairooz F. Kabbinavar, Joachim Von Pawel, Jean-Charles Soria, Colombe Chappey, Ahmad Mokatrin, Alan Sandler, Daniel Waterkamp, David R. Spigel. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting abstract TPS8123. [http://meetinglibrary.asco.org/content/128983-144 link to abstract]</ref><ref>[http://www.roche.com/media/store/releases/med-cor-2015-08-17.htm Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer] Roche.com, 8/17/2015.</ref> | ||
| − | == | + | ==Preliminary data== |
| − | + | ===[[Non-small cell lung cancer]]=== | |
| + | # Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Mar 9. [Epub ahead of print] [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00587-0/fulltext link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/26970723 PubMed] | ||
==Also known as== | ==Also known as== | ||
| Line 17: | Line 18: | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Anti-PD-L1 antibodies]] | [[Category:Anti-PD-L1 antibodies]] | ||
| + | |||
| + | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 11:17, 29 April 2016
General information
Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.[1][2]
Preliminary data
Non-small cell lung cancer
- Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Mar 9. [Epub ahead of print] link to original article PubMed
Also known as
- RG7446
References
- ↑ Naiyer A. Rizvi, Laura Quan Man Chow, Luc Yves Dirix, Scott N. Gettinger, Michael S. Gordon, Fairooz F. Kabbinavar, Joachim Von Pawel, Jean-Charles Soria, Colombe Chappey, Ahmad Mokatrin, Alan Sandler, Daniel Waterkamp, David R. Spigel. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting abstract TPS8123. link to abstract
- ↑ Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer Roche.com, 8/17/2015.